These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
538 related articles for article (PubMed ID: 27986708)
1. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708 [TBL] [Abstract][Full Text] [Related]
2. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review. Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479 [TBL] [Abstract][Full Text] [Related]
3. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor. Egger A; Coello D; Kirsner RS; Brehm JE J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687 [TBL] [Abstract][Full Text] [Related]
4. Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm. Lane AA Hematol Oncol Clin North Am; 2020 Jun; 34(3):589-600. PubMed ID: 32336422 [TBL] [Abstract][Full Text] [Related]
6. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495 [No Abstract] [Full Text] [Related]
7. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. Pemmaraju N Curr Hematol Malig Rep; 2017 Dec; 12(6):510-512. PubMed ID: 29064022 [No Abstract] [Full Text] [Related]
8. Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature. Beziat G; Ysebaert L; Gaudin C; Steinmeyer Z; Balardy L Leuk Res; 2019 Oct; 85():106199. PubMed ID: 31415942 [No Abstract] [Full Text] [Related]
9. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851 [TBL] [Abstract][Full Text] [Related]
10. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Liu J; Li S; Wang Q; Feng Y; Xing H; Yang X; Guo Y; Guo Y; Sun H; Liu X; Yang S; Mei Z; Zhu Y; Cheng Z; Chen S; Xu M; Zhang W; Wan N; Wang J; Ma Y; Zhang S; Luan X; Xu A; Li L; Wang H; Yang X; Hong Y; Xue H; Yuan X; Hu N; Song X; Wang Z; Liu X; Wang L; Liu Y Blood; 2024 May; 143(18):1825-1836. PubMed ID: 38211332 [TBL] [Abstract][Full Text] [Related]
11. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081 [TBL] [Abstract][Full Text] [Related]
12. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002 [TBL] [Abstract][Full Text] [Related]
13. Enhancing venetoclax activity in hematological malignancies. Satta T; Grant S Expert Opin Investig Drugs; 2020 Jul; 29(7):697-708. PubMed ID: 32600066 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Konopleva M; Pollyea DA; Potluri J; Chyla B; Hogdal L; Busman T; McKeegan E; Salem AH; Zhu M; Ricker JL; Blum W; DiNardo CD; Kadia T; Dunbar M; Kirby R; Falotico N; Leverson J; Humerickhouse R; Mabry M; Stone R; Kantarjian H; Letai A Cancer Discov; 2016 Oct; 6(10):1106-1117. PubMed ID: 27520294 [TBL] [Abstract][Full Text] [Related]
15. Venetoclax: Targeting BCL2 in Hematological Cancers. Scheffold A; Jebaraj BMC; Stilgenbauer S Recent Results Cancer Res; 2018; 212():215-242. PubMed ID: 30069633 [TBL] [Abstract][Full Text] [Related]
16. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. Wilson NR; Konopleva M; Khoury JD; Pemmaraju N Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167 [TBL] [Abstract][Full Text] [Related]
17. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256 [TBL] [Abstract][Full Text] [Related]
18. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348 [TBL] [Abstract][Full Text] [Related]
19. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569 [TBL] [Abstract][Full Text] [Related]
20. [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review]. Shi J; Xu N; Niu Y; Jia SX; Yang CM; Fang MY Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):86-89. PubMed ID: 38527844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]